|20th October 2020||Michelle Kumbier||162||Grant/award etc.||$0.00|
|12th October 2020||Roxanne S Austin||8,000||Open or private sale||$149.23||$1,193,840.00|
|5th October 2020||Roxanne S Austin||2,000||Open or private sale||$145.73||$291,460.00|
|1st October 2020||Roxanne S Austin||10,000||Open or private sale||$141.13||$1,411,300.00|
|1st October 2020||Roxanne S Austin||30,000||Open or private sale||$140.50||$4,215,000.00|
|1st October 2020||Roxanne S Austin||40,000||Open or private sale||$144.99||$5,799,600.00|
|1st October 2020||Gregory A Ahlberg||1,490||Grant/award etc.||$0.00|
|1st October 2020||Roxanne S Austin||10,000||Open or private sale||$145.49||$1,454,900.00|
|30th September 2020||Andrea F Wainer||30,000||Exercise of derivative||$38.40||$1,152,000.00|
|30th September 2020||Andrea F Wainer||30,000||Open or private sale||$107.01||$3,210,360.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 2/10.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other.